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Objectives: The objective was to analyze current trends in consumption as well 
as prescription practice pattern of the new anti-RANKL monoclonal antibody 
denosumab in the treatment of osteoporosis since its introduction onto the mar-
ket in the Czech Republic in 2011. MethOds: The prescription-based database of 
the General Health Insurance Company (VZP) of the CR that covers approximately 
62% of the Czech population was used as the data source. An insured person with 
a recorded prescription for denosumab in the period of interest was defined as a 
patient. The obtained epidemiological and costing data were also confronted with 
the prediction in the budget impact analysis in the public reimbursement dossier 
accessible in the State Institute for Drug Control files. Results: A total of 3119 (158) 
patients (men) treated with denosumab were identified in the first year, i.e. between 
August 2011 and July 2012. The median age of patients was 73 years. Of the patients 
prescribed denosumab in the first half-year, 84% received the second dose within 
the observed period of one year, of which 85% within the authorized period of 6 
months (+-1 month). This new drug was most often prescribed by physicians trained 
in internal medicine (47%) and rheumatology (30%). The cumulative costs for VZP 
of the drug were CZK 27.3 mil (EUR 1.1. mil) in the first year. cOnclusiOns: The 
uptake of denosumab has been rapid and agrees with the predictions presented by 
the manufacturer before the launch of the drug. This preliminary data also suggest 
that both the prescribing doctors and the patients filling the prescriptions follow 
the dosing schedule.
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Objectives: To describe the clinical profile of patients with rheumatoid arthri-
tis (RA) treated with biologic agents within the former Italian centers “Antares” 
where autoimmune diseases are treated. MethOds: This study analyzed data from 
patient diaries (PDS), which involved 70 rheumatologists that are regular prescribers 
of biological treatments for rheumatoid arthritis and were recruited by telephone. 
The patient diaries were completed via web. Results: Study population consisted 
of 206 (45.9%) patients with RA, 160 (35.6%) with psoriatic arthritis, 61 (13.6%) with 
ankylosing spondylitis, 14 (3.1%) with Juvenile idiopathic arthritis and 8 (1.8%) with 
early RA. Female gender prevailed, while the most numerous age group was the 
one that ranged from 50 to 60 years. The disease was mostly diagnosed before 50 
years old and, despite in the group of patients treated with biologic drugs for more 
than 3 months the percentage of subjects with a value of HAQ less than 1 is higher 
when compared with those of patients whose treatment has begun more recently, 
the proportion of patients with a value of HAQ between 2 and 3 is still 40.0%. The 
same, half of the subjects treated for more than 3 months still have a moderate or 
high disease activity (DAS28 ≥ 3.2). cOnclusiOns: The study sample was in line 
with the literature concluding that it is representative of the Italian context. The 
fact that there is a proportion of patients treated with biological therapy for more 
than three months, as well as an important number of patients who have been 
treated with more than one biologic drugs, and that have a perception of quality of 
life rather low and / or a disease activity state rather active, leads to conclude that 
there is still a type of patient for which new therapeutic options should be evaluated.
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Objectives: Osteoporosis is a common health problem among elderly popula-
tion. Patients with osteoporosis are exposed to low-energy fractures. The preva-
lence of the disease varies significantly throughout the country due to the strong 
correlation with demographic factors. National guidelines recommend secondary 
prevention for all osteoporosis patients suffering from low-energy fractures. The 
aim of treatment is to prevent further fractures. In order to effectively allocate the 
resources needed for osteoporosis treatment, it is essential to know the number 
of patients and treatment practices in local level. MethOds: Local registry data 
was used to estimate the total population with low-energy fractures, as well as 
to recognize the differences in treatment of osteoporosis in each hospital district 
(n= 21) and municipality (n= 320). Data on hip fractures from year 2009 was extrapo-
lated to year 2012 using demographic data. The overall prevalence of low-energy 
fractures was estimated trough a distribution of different fracture types available 
from literature. A map-based application was built (Tableau 8) to visualize the dif-
ferences in the prevalence and treatment of osteoporosis across Finland. The model 
enables comparison between municipalities or hospital districts. Results: The 
estimated number of osteoporotic fractures was 1733, in a hospital district with 
250,000 inhabitants (Northern-Savo). The estimated prevalence rates in different 
municipalities within the hospital district varied between 0.52–1.7/100 inhabit-
ants. Simultaneously, basic reimbursement for medical treatment (ATC:M05B) was 
paid for 1.2/100 inhabitants - the range among elderly population (> 65y) was 3.21– 
6.56/100 inhabitants. cOnclusiOns: There are significant local differences in the 
prevalence of osteoporosis as well as in its treatment. The population demographics 
do not explain the observed differences in the consumption of osteoporosis medica-
tion between different municipalities. The developed map-based application gives 
multiple possibilities to analyze these issues through data visualization. With this 
approach the interventions may be targeted to areas needing it the most.
of the knee, musculoskeletal pain and headache have been published however no 
reviews have incorporated the latest trial evidence from the recent large scale high 
quality RCTs to generate EQ-5D scores. MethOds: An individual patient level data 
(IPD) based Mixed Treatment Comparison (MTC) was undertaken using a database 
of 28 recent, high quality RCTs containing observations for over 18,000 patients. 
The analysis evaluated the effectiveness of acupuncture in terms of continuous 
outcomes, for each of the three conditions over a three month time horizon, map-
ping generic and disease-specific measures to generate EQ-5D scores and using 
published mapping algorithms unless none were available. Results: Acupuncture, 
net of sham, is more effective in that it generates greater EQ-5D scores compared to 
usual care in the management of chronic, non-cancer pain in primary care. Using 
a random effects IPD MTC, the change in EQ-5D scores from baseline to 3 months 
was mean 0.0419 (95% credibility interval 0.0066 to 0.0765) for acupuncture net 
of sham and 0.0573 (95% credibility interval 0.0139 to 0.1006) for acupuncture vs 
usual care. cOnclusiOns: Based on EQ-5D scores, this analysis suggests that 
acupuncture, is the most effective option. The analyses synthesise effectiveness 
evidence using MTC of IPD whilst controlling for sham effect. This analysis is an 
intermediate step to inform a full cost-effectiveness analysis to support decision-
making in the UK.
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Objectives: As outcomes research methodologies advance, they should increas-
ingly allow access by different disciplines as clinicians, epidemiologists, econo-
mists, and statisticians interact frequently. A data visualization tool can present 
complex patterns effectively to a diverse audience. The objective of this study 
was to present treatment patterns among Veterans Health Administration (VHA) 
patients diagnosed with ankylosing spondylitis (AS) using advanced data visuali-
zation techniques. MethOds: Using the VHA Medical SAS®dataset, adult patients 
with at least one AS diagnosis (ICD-9-CM: 720.0) were selected. Prescriptions for 
anti-tumor necrosis factor (anti-TNF) and non-TNF agents were identified. For 2 
years after the date of the first prescription (initiation date), drug switches and 
discontinuation were examined. Using a processing language, a data visualization 
tool was developed to demonstrate changes in treatment patterns after the first 
and second treatment switches. Results: A total of 1,021 AS patients initiated 
therapy with TNF, of which 13.52% switched to another TNF, 0.20% switched to a 
non-TNF, 49.56% discontinued therapy and 36.73% continued their initial therapy. 
Among patients who switched to another TNF, 60.87% remained on the switched 
therapy, while 31.16% discontinued therapy, 7.97% switched to another TNF, and 
no patients switched to a non-TNF. 81.82% of patients who made a second switch 
to a TNF medication remained on this TNF, while 9.09% discontinued treatment. 
A total of 84 AS patients initiated therapy with a non-TNF. 4.76% of these patients 
switched to a TNF, 1.19% switched to another non-TNF, 93.61% discontinued therapy 
and no patients continued treatment. Of those patients whose first switch was to a 
TNF, 50% continued therapy while the remaining 50% discontinued. There were no 
second switches. cOnclusiOns: When analyzing several years of data including 
treatment (dis)continuation and switches, treatment patterns can be difficult to 
capture. Data visualization tools help present complicated flows effectively for a 
diverse research audience.
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Objectives: Recent research has suggested that patients may have a “window of 
opportunity” to reverse immune dysregulation associated with RA onset through 
aggressive early treatment. This study aimed to evaluate the outcomes associ-
ated with early versus late biologic treatment in RA. MethOds: Adults (≥ 18 
years) with confirmed RA diagnosis between January 2008 and December 2010, 
who received biologic therapy for ≥ 3 months and had ≥ 12 months follow-up 
were included in this retrospective, observational medical chart review study in 
Spain, Germany, and United Kingdom. Physicians abstracted outcomes including 
28-joint disease activity scores (DAS28) alongside treatment received. Patients 
were classified as receiving early biologic treatment if started within 1 year of 
RA diagnosis. Outcomes included DAS28 reduction of ≥ 1.2 from scores at biologic 
start and remission (DAS28< 2.6). Time to reaching these outcomes was evaluated 
using Kaplan-Meier survival curves and log rank tests. Results: Of 328 patients 
included, 310 (178 early; 132 late) had DAS28 measurements and were demographi-
cally similar between early vs. late treatment (overall: mean age 47.9 at diagno-
sis, 71.0% female, 96.1% white). Overall, 73.5% of patients had a DAS28 decrease 
≥ 1.2 points and 44.5% achieved remission. More early versus late biologic treated 
patients had a DAS28 decrease ≥ 1.2 (79.2% vs 65.9%, p= 0.009) but there was no 
significant difference in the time to this decrease. More early vs. late biologic 
treated patients achieved remission (51.1% vs. 35.6%, p= 0.009), with a significant 
difference in survival curves when indexing on time since RA diagnosis (p< 0.001) 
and biologic start (p= 0.024). There were no significant differences outcomes across 
countries. cOnclusiOns: This chart review contributes to the growing literature 
surrounding outcomes associated with early biologic treatment. Within this study, 
RA patients who were treated early were more likely to achieve clinically signifi-
cant improvement and to reach remission earlier in their RA disease trajectory 
than those treated later.
